Status:

NOT_YET_RECRUITING

A New Diagnostic Paradigm for Retinitis Pigmentosa Secondary to USH2A Pathogenic Variants

Lead Sponsor:

IRCCS Ospedale San Raffaele

Conditions:

USH2A Variant Retinitis Pigmentosa

Eligibility:

All Genders

18+ years

Brief Summary

Aim of the study is to perform a non-invasive multimodal retinal imaging investigation in a cohort of patients affected by USH2A retinitis pigmentosa (USH2A-RP), in order to develop a new diagnostic p...

Eligibility Criteria

Inclusion

  • age \>18 years
  • genetically confirmed diagnosis of USH2A-RP
  • availability of genetic tests to assess the pathogenic variants

Exclusion

  • inability to understand and sign the written informed consent form
  • any inflammatory, infectious or degenerative eye disease
  • media opacities resulting incompatible with good imaging quality
  • uncontrolled systemic, metabolic, autoimmune neuroinflammatory and neurodegenerative disease
  • ophthalmologic surgery within the previous six months

Key Trial Info

Start Date :

August 1 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 1 2027

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06545253

Start Date

August 1 2024

End Date

February 1 2027

Last Update

August 9 2024

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A New Diagnostic Paradigm for Retinitis Pigmentosa Secondary to USH2A Pathogenic Variants | DecenTrialz